

PRODUZIONE BIBLIOGRAFICA PIU' RILEVANTE

Nel corso del 2009, le attività dei ricercatori dell'ISS, nei campi descritti in questa relazione, hanno prodotto lavori pubblicati su riviste nazionali ed internazionali, riportate in Pub-Med, molte delle quali con alto "impact factor", a testimonianza della qualità della ricerca e dell'intervento condotti in ISS. Alcune tra le più significative pubblicazioni sono riportate di seguito.

1. Fanales-Belasio E., Moretti S., Fiorelli V., Tripiciano A, Pavone-Cossut M.R., Scoglio A., Collacchi B., Nappi F., Macchia I., Bellino S., Francavilla V., Caputo A., Barillari G., Magnani M., Laguardia M.E., Cafaro A., Titti F., Monini P., Ensoli F., and Ensoli B. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response which appears prevalent in the asymptomatic stage of infection. *J. Immunol.*, 182:2888-2897, 2009.
2. Monini P., Sgadari C., Grosso M.G., Bellino S., Di Biagio A., Toschi E., Bacigalupo I., Sabbatucci M., Cencioni G., Salvi E., Leone P., and Ensoli B. for the Concerted Action on Kaposi's Sarcoma (Barillari G., Moracci G., Carratelli L., Gatti G., Brambilla L., Brambati M., Ferrucci S., De Pità O., Pilla M.A., Di Carlo A., Giuliani M., Cottoni F., Cuccuru M.A., Calvieri S., Clerico R., Potenza C., Tirelli U., Simonelli C., Martellotta F., Borghi A., Del Giacco S., Moi L., Piludu G., Sirianni M.C., Campagna M., Sarmati L., Andreoni M., Bianchini G., Sheldon J., Milzer J., Schulz T.). Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor Indinavir. *AIDS J.*, 23:534-538, 2009.
3. Florese R.H., Demberg T., Xiao P., Kuller L., Larsen K., Summers E.L., Venzon D., Cafaro A., Ensoli B., and Robert-Guroff M. Contribution of non-neutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared to multigenic vaccines. *J. Immunol.*, 182:3718-27, 2009.
4. Borsetti A., Baroncelli S., Maggiorella M.T., Moretti S., Fanales Belasio E., Sernicola L., Tripiciano A., Macchia I., Michelini Z., Belli R., Farcomeni S., Pavone-Cossut M.R., Negri D., Caputo A., Bellino S., Buttò S., Titti F., Cafaro A., and Ensoli B. Containment of infection in Tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P_{cy243}. *Viral Immunol.*, 22:117-24, 2009.

5. Longo O., Tripiciano A., Fiorelli V., Bellino S., Scoglio A., Collacchi B., Ruiz Alvarez M.J., Francavilla V., Arancio A., Paniccia G., Lazzarin A., Tambussi G., Tassan Din C., Visintini R., Narciso P., Antinori A., D’Offizi G., Giulianelli M., Carta M., Di Carlo A., Palamara G., Giuliani M., Laguardia M.E., Monini P., Magnani M., Ensoli F., and Ensoli B. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine (special issue, from the: “6th World Congress on Vaccines, Immunisation and Immunotherapy 2008”, Milan, Italy; September 23-September 25, 2008), 27:3306-3312, 2009.
6. Caputo A., Castaldello A., Brocca-Cofano E., Voltan R., Bortolazzi F., Altavilla G., Sparnacci K., Laus M., Tondelli L., Gavioli R., and Ensoli B. Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration. Vaccine, 27:3605-3615, 2009.
7. Voltan R., Castaldello A., Brocca-Cofano E., De Michele R., Triulzi C., Altavilla G., Tondelli L., Laus M., Reali E., Gavioli R., Ensoli B., Caputo A. Priming with a very low dose of DNA complete with cationic block copolymers followed by protein boosts elicits broad and long-lasting antigen-specific humoral and cellular responses in mice. Vaccine, 27:4498–4507, 2009.
8. De Maria A., Ugolotti E., Rutjens E., Mazza S., Radic L., Faravelli A., Koopman G., Di Marco E., Costa P., Ensoli B., Cafaro A., Mingari M.C., Moretta L., Heeney J., Biassoni R. NKp44 expression, phylogenesis and function in non-human primate NK cells. Int. Immunology, 21:245-255, 2009. [I.F. 3.181]
9. Cafaro A., Macchia I., Maggiorella M.T., Titti F., and Ensoli B. Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS. In: Pharmaceutical Biotechnology (Guzman C.A. and Fuerstein G. Eds.), Chapter No. 14, pp. 189-242, Publisher: Landes Bioscience/Eurekah, USA, 2009.
10. Caputo A., Gavioli R., Bellino S., Longo O., Tripiciano A., Francavilla V., Sgadari C., Paniccia G., Titti F., Cafaro A., Ferrantelli F., Monini P., Ensoli F., and Ensoli B. HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. Int. Reviews Immunol., 28:285–334, 2009.

11. Barillari G., Toschi E., Sgadari C., Monini P. and Ensoli B. The formation of new blood vessels in Kaposi's sarcoma. *In: The Research Signpost* (Kaposi Sarcoma: A model of Oncogenesis, 2010; Stebbing J., Pantanowitz L., Dezube B. Eds.), Publisher: The Research Signpost, USA, Chapter 6, pp. 101-122, 2009.
12. Nappi F., Chiozzini C., Bordignon V., Borsetti A., Bellino S., Cippitelli M., Barillari G., Caputo A., Tyagi M., Giacca M., and Ensoli B. Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation-independent mechanism which require binding of Tat to viral particles. *J. Gene Med.*, 11:955–965, 2009.
13. Ensoli B., Fiorelli V., Ensoli F., Lazzarin A., Visintini R., Narciso P., Di Carlo A., Tripiciano A., Longo O., Bellino S., Francavilla V., Paniccia G., Arancio A., Scoglio A., Collacchi B., Ruiz Alvarez M.J., Tambussi G., Tassan Din C., Palamara G., Latini A., Antinori A., D'Offizi G., Giuliani M., Giulianelli M., Carta M., Monini P., Magnani M., and Garaci E. The preventive phase I trial with the HIV-1 Tat based vaccine. *Vaccine*, 28:371–378, 2009.
14. Bellino S., Francavilla V., Tripiciano A., Paniccia G., Arancio A., Fiorelli V., Scoglio A., Collacchi B., Campagna M., Lazzarin A., Tambussi G., Tassan Din C., Visintini R., Narciso P., Antinori A., D'Offizi G., Giulianelli M., Carta M., Di Carlo A., Palamara G., Giuliani M., Laguardia M.E., Monini P., Magnani M., Ensoli F., and Ensoli B. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. *Recent Rev. Clin. Trials*, 4:195-204, 2009.
15. Buttò S. and Ensoli B. AIDS: aggiornamenti epidemiologici e terapeutici sulla sindrome da immunodeficienza acquisita. *Enciclopedia Treccani*, accettato nel 2009.

16. Pezzoli M.C., El Hamad I., Scarcella C., Vassallo F., Speziani F., Cristini G, Scolari C., Suligo B, Luzi A.M., Bernasconi D., Lichtner M., Cassarà G., Manca N, Carosi G, Castelli F., and the PRISHMA Study Group (Grassi E., Ricci A., Rodella A., Affronti M., Prestileo T., Baglio G., Buttò S., Cacciani L., Colucci A., Cuomo R., Gallo P., Regine V., Vullo V.). HIV Infection among illegal migrants, Italy, 2004–2007. Emerging Infectious Diseases, 15: 1802-04, 2009.
17. Suligo B, Quaglio G, Regine V, Ramadani N, Bertinato L, Cami A, Dentico P, Volpe A, Figliomeni M, Camoni L, Putoto G, Rezza G. Seroprevalence of HIV, HSV-2, and *Treponema pallidum* in the Kosovarian population. Scand J Infect Dis., 41:608-13, 2009.
18. Camoni L, Federico B, Capelli G, Regine V, Salfa MC, Nicoletti G, Canuzzi P, Magliocchetti N, Rezza G, Suligo B; SERT Study Group. Few Italian Drug Users Undergo HIV Testing. AIDS Behav., 2009 Oct 6.
19. Camoni L, Regine V, Colucci A, Conte ID, Chiriotta M, Vullo V, Sebastiani M, Cordier L, Beretta R, Fiore JR, Tateo M, Affronti M, Cassarà G, Suligo B. Changes in at-risk behavior for HIV infection among HIV-positive persons in Italy. AIDS Patient Care STDS, 23:853-8, 2009.
20. Camoni L, Federico B, Capelli G, Salfa MC, Regine V, Nicoletti G, Canuzzi P, Magliocchetti N, Suligo B; Gruppo di Studio sui SERT. Proportion of drug users in treatment who have never undergone serological testing for HIV, HBV and HCV and correlates of failure to undergo testing: Italy, 2005-2007 Ann Ig, 21:315-27, 2009.
21. Serraino D, Dal Maso L, De Paoli A, Zucchetto A, Bruzzone S, Camoni L, Suligo B. On changes in cancer mortality among HIV-infected patients: is there an excess risk of death from pancreatic cancer? Clin Infect Dis., 49:481-2 2009.
22. Serraino D, Zucchetto A, Suligo B, Bruzzone S, Camoni L, Boros S, De Paoli A, Dal Maso L, Franceschi S, Rezza G. Survival after AIDS diagnosis in Italy, 1999-2006: a population-based study. J Acquir Immune Defic Syndr., 52:99-10, 2009.
23. Camoni L, Regine V, Salfa MC, Nicoletti G, Canuzzi P, Magliocchetti N, Rezza G, Suligo

- B; Sert Study Group. Prevalence and correlates of infection with human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among drug users in Italy: a cross-sectional study. Scand J Infect Dis., 41:520-3, 2009.
24. Guy R, Gold J, Calleja JM, Kim AA, Parekh B, Busch M, Rehle T, Hargrove J, Remis RS, Kaldor JM; WHO Working Group on HIV Incidence Assays. Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect Dis., 9:747-59, 2009.
25. Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, Russo A, Intrieri T, Vercelli M, Zambon P, Tagliabue G, Zanetti R, Federico M, Limina RM, Mangone L, De Lisi V, Stracci F, Ferretti S, Piffer S, Budroni M, Donato A, Giacomini A, Bellù F, Fusco M, Madeddu A, Vitarelli S, Tessandori R, Tumino R, Suligo B, Franceschi S; Cancer and AIDS Registries Linkage (CARL) Study. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer., 100:840-7, 2009.
26. Zucchetto A, Bruzzone S, De Paoli A, Regine V, Pappagallo M, Dal Maso L, Serraino D, Rezza G, Suligo B. AIDS and injecting drug use: survival determinants in the highly active antiretroviral therapy era. Epidemiol Prev., 33:184-9, 2009.
27. Raimondo M, Camoni L, Regine V, Salfa MC, Suligo B. L'HIV nella popolazione straniera in Italia. Notiziario Ist. Super. Sanità, 22:11-14, 2009.
28. Camoni L, D'Amato S, Pasqualini C, Regine V, Salfa MC, Raimondo M, Pompa MG, Suligo B. La sorveglianza dell'infezione da HIV: proposta per una scheda di raccolta dati più dettagliata. Notiziario Ist Super Sanità 2009;22(5):11-15.
29. Muratori C, Bona R, Ruggiero E, D'Ettorre G, Vullo V, Andreotti M, Federico M. DC contact with HIV-1-infected cells leads to high levels of Env-mediated virion endocytosis coupled with enhanced HIV-1 Ag presentation. Eur J Immunol., 39:404-16, 2009.
30. Olivetta E., Mallozzi C., Ruggieri V., Pietraforte D., Federico M., Sanchez M. HIV-1 Nef induces p47phox phosphorylation leading to a rapid superoxide anion release from U937 human monoblastic cell line. J. Cell. Biochem., 106: 812-822, 2009.

31. C. Muratori, E. Ruggiero, A. Sistigu, R. Bona and M. Federico. Human Immunodeficiency virus type 1 (HIV-1) protease inhibitors block cell-to-cell HIV-1 endocytosis in dendritic cells. J. Gen. Virol., 90:2777-87, 2009.
32. G.B. Kyey, C. Dinkins, A.S. Davis, E. Roberts, S.B. Singh, C. Dong, L. Wu, E. Kominami, T. Ueno, A. Yamamoto, M. Federico, A. Panganiban, I. Vergne and V. Deretic. Autophagy pathway intersects with HIV-1 biosynthesis and regulates viral yields in macrophages J. Cell. Biol., 186: 255-268, 2009.
33. C. Muratori, L.E. Cavallin, K. Ktatzel, A. Tinari, A. De Milito, S. Fais, P. D' Aloja, M. Federico, V. Vullo, A. Fomina, E. A. Mesri, F. Superti, and A.S. Baur. Massive secretion by T cells is caused by HIV Nef in infected cells and by Nef transfer to bystander cells. Cell Host & Microbe. 6: 1-13, 2009.
34. P. Di Bonito, F. Grasso, S. Mochi, L. Petrone, E. Fanales-Belasio, A. Mei, A. Cesolini, G. Laconi, H. Conrad. H. Bernhard, C.J. Dembek, A. Cosma, S.M. Santini, C. Lapenta, S. Donati, C. Muratori, C. Giogi, and M. Federico. Anti-tumor CD8+ cell immunity elicited by HIV-1 based Virus-Like Particles incorporating HPV-16 E7 protein. Virology. 395, 45-55, 2009.
35. Ridolfi B, Catone S, Sgarbanti M, Sernicola L, Battistini A, Parolin C, Titti F, Borsetti A
Generation of a human immunodeficiency virus type 1 chronically infected monkey B cell line expressing low levels of endogenous TRIM5alpha. J Cell Physiol., 221:760-5, 2009.
36. Mee ET, Berry N, Ham C, Sauermann U, Maggiorella MT, Martinon F, Verschoor EJ, Heeney JL, Le Grand R, Titti F, Almond N, Rose NJ. Mhc haplotype H6 is associated with sustained control of SIVmac251 infection in Mauritian cynomolgus macaques. Immunogenetics, 61:327-39, 2009.
37. Titti F., Hammer DS, HIV/AIDS vaccine: rumors and lights on T cell-based vaccine. Fut Virology, 4:121-126, 2009.
38. Baroncelli S, Galluzzo CM, Pirillo MF, Mancini MG, Weimer LE, Andreotti M, Amici R, Vella S, Giuliano M, Palmisano L. Microbial translocation is associated with residual

- replication in HAART-treated HIV+ subjects with <50 copies/ml HIV-1 RNA. J. Clin. Virol., 46:367-70, 2009.
39. Andreotti M, Galluzzo CM, Guidotti G, Germano P, Altan AD, Pirillo MF, Marazzi MC, Vella S, Palombi L, Giuliano M. Comparison of HIV type 1 sequences from plasma, cell-free breast milk, and cell-associated breast milk viral populations in treated and untreated women in Mozambique. AIDS Research and Human Retroviruses, 25:707-11, 2009.
40. Palmisano L, Galluzzo CM, Giuliano M. The importance of testing genotypic resistance in proviral DNA of patients fully responding to highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr., 51:233-4, 2009.
41. Palmisano L, Giuliano M, Galluzzo CM, Amici R, Andreotti M, Weimer LE, Pirillo MF, Fragola V, Bucciardini R, Vella S. The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy. HIV Med., 10:477-81, 2009.
42. Palmisano L, Giuliano M, Bucciradini R, Andreotti M, Fragola V, Pirillo MF, Weimer LE, Mancini MG, Vella S. Modifications of residual viremia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions. J. Med. Microbiol., 58:121-4, 2009.
43. Pinnetti C, Floridia M, Cingolani A, Visconti E, Cavaliere AF, Celentano A, Tamburrini E. Effect of HCV infection on glucose metabolism in pregnant women with HIV receiving HAART. HIV Clin. Trials, 10:403-12, 2009.
44. Floridia M, Tamburrini E, Anzidei G, Tibaldi C, Guaraldi G, Guerra B, Meloni AM, Vimercati A, Molinari A, Pinnetti C, Dalzero S, Ravizza M; Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy. AIDS Patient Care STDS, 23:147-52, 2009.
45. Meloni A, Tuveri M, Floridia M, Zucca F, Borghero G, Gariel D, Melis GB. Pregnancy care in two adolescents perinatally infected with HIV. AIDS Care, 21:796-8, 2009.
46. Baroncelli S; Tamburrini E, Ravizza M, Dalzero S, Tibaldi C, Ferrazzi E, Anzidei G, Fisco M, Alberico S, Martinelli P, Placido G, Guaraldi G, Pinnetti C, Floridia M; Italian Group on

- Surveillance on Antiretroviral Treatment in Pregnancy. AIDS Patient Care STDS, 23:513-20, 2009.
47. Guaraldi G, Cocchi S, Motta A, Ciaffi S, Codeluppi M, Bonora S, Di Benedetto F, Masetti M, Floridia M, Baroncelli S, Pinetti D, Bertolini A, Gerunda GE, Esposito R. Efficacy and safety of atazanavir in patients with end-stage liver disease. Infection, 37:250-5, 2009.
48. Bonora S, Nicastrì E, Calcagno A, Gonzales de Requena D, D’Ettorre G, Sarmati L, Palmisano L, Vullo V, Di Perri G, Andreoni M. Ultrasensitive assessment of residual HIV viremia in HAART-treated patients with persistently undetectable plasma HIV-RNA : a cross-sectional evaluation. J. Med. Virol., 81:400-5, 2009.
49. d’Ettorre G, Ceccarelli G, Turriziani O, Andreotti M, Masetti P, Rizza C, Vella S, Antonelli G, Mastroianni CM, Vullo V. The absence of HIV mutations in cerebrospinal fluid and in peripheral blood mononuclear cells during a regimen containing Trizivir plus tenofovir. J. Chemother., 21:455-7, 2009.
50. Michelini Z, Negri DR, Baroncelli S, Spada M, Leone P, Bona R, Klotman ME, Cara A. Development and use of SIV-based integrase defective lentiviral vector for immunization. Vaccine, 27:4622-9, 2009.
51. Narciso P, Bucciardini R, Tozzi V, Bellagamba R, Ivanovic J, Giulianelli M, Scevola S, Palummieri A, Fragola V, Massella M, Fracasso L, De Vita R. Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study. AIDS Research and Human Retroviruses, 25:979-87, 2009.